R&D Pipeline
Kyntra Bio is dedicated to creating innovative, first-in-class medicines for the treatment of chronic, life-threatening, and debilitating conditions, such as mCRPC and anemia associated with LR-MDS.
Our investigational products are not limited to single indications—they represent broader therapeutic platforms designed to target key biological pathways and mediators involved in multiple diseases. This approach enables us to pursue high-impact opportunities across a range of conditions with shared molecular drivers.
ROXADUSTAT (HIF-PH inhibitor)
Anemia in Patients with Lower-Risk Myelodysplastic Syndrome
Phase 3 - Ready
FG-3246
(CD46-TARGETING ADC)
Metastatic Castration-Resistant Prostate Cancer
Phase 2
FG-3180
(CD46-TARGETING PET IMAGING AGENT)
Metastatic Castration-Resistant Prostate Cancer,
Phase 2
FG-3246
FG-3246 is a potential first-in-class, fully human ADC targeting CD46. It is currently in development for mCRPC and has the potential for additional trials targeting other CD46-expressing cancers. As part of the program, Kyntra Bio is also developing FG-3180, a CD46-targeted PET imaging agent designed to support patient selection by identifying CD46-positive lesions.
Roxadustat
Roxadustat is the first oral HIF-PH inhibitor to launch globally. It promotes erythropoiesis, or red blood cell production, by stimulating endogenous erythropoietin production, enhancing iron absorption and mobilization, and downregulating of hepcidin.
